| Name | Title | Contact Details |
|---|
Arch Insurance Group Inc., a division of Arch Capital Group Ltd. (ACGL), is a market-leading specialty insurer. We provide a wide range of property, casualty and specialty insurance for corporations, professional firms and financial institutions across the United States and Canada. Our insurance group in North America consists of Arch Insurance Company, Arch Specialty Insurance Company and Arch Excess & Surplus Insurance Company. Arch Insurance Groups executive offices are located at One Liberty Plaza in New York City, with regional offices located in New York City (Northeast Region), Atlanta (Southeast Region), Chicago (Central Region) and San Francisco (Western Region), as well as other offices throughout the U.S. to support our business. Arch Insurance Company also operates a branch office in Toronto, Canada. ACGL is a Bermuda public limited liability company that provides insurance, reinsurance and mortgage insurance on a worldwide basis through operations in Bermuda, the United States, Canada, Europe, Australia and Hong Kong.
Liverpool Football Club was founded in 1892 and is one of the worlds most historic and famous football clubs. Honours include 19 League Titles, eight FA Cups, ten League Cups, six European Cups, three UEFA Cups, four European Super Cups, 16 Charity Shields, one FIFA Club World Cup, two Womens Super League and one Womens Championship. As a socially responsible club, Liverpool FC is proud of its heritage and plays a proactive role in its communities through its official charity, Liverpool FC Foundation, which helps children and families in Merseyside and beyond, and the Red Neighbours programme, which creates events and experiences specifically aimed at improving the lives of those living in and around the Anfield area (L4, L5 and L6). Liverpool FC is a global brand and works with leading edge commercial partners around the world providing unparalleled commercial opportunities.
A private Class C Bermuda-based reinsurance company offering customized solutions to address our clients unique needs.
Fisher Barton is a prominent manufacturing company with over 50 years of experience, founded in 1973 by metallurgist Richard L. Wilkey. Headquartered in Watertown, Wisconsin, the company has grown to employ more than 900 people worldwide. It operates as a group of independent manufacturing companies, including Fisher Barton Blades and Thermal Spray Technologies. The company specializes in materials and surface engineering, offering a diverse range of products such as industrial knives, lawnmower blades, agricultural knives, and thermal spray coatings. Fisher Barton is recognized for its metallurgical expertise, supported by an in-house lab that enhances product development and quality assurance. The company serves major clients, including John Deere, and has been acknowledged for its excellence in supply and innovation. Fisher Barton continues to focus on technological advancements and employee development to maintain its leadership in the industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.